Erratum: Non-nucleoside reverse transcriptase inhibitor efavirenz activates PXR to induce hypercholesterolemia and hepatic steatosis (Journal of Hepatology (2019) 70(5) (930–940), (S0168827819300297), (10.1016/j.jhep.2018.12.038))

Taesik Gwag; Zhaojie Meng; Yipeng Sui; Robert N. Helsley; Se Hyung Park; Shuxia Wang; Richard N. Greenberg; Changcheng Zhou

doi:10.1016/j.jhep.2021.01.003

Erratum: Non-nucleoside reverse transcriptase inhibitor efavirenz activates PXR to induce hypercholesterolemia and hepatic steatosis (Journal of Hepatology (2019) 70(5) (930–940), (S0168827819300297), (10.1016/j.jhep.2018.12.038))

Taesik Gwag
, Zhaojie Meng
, Yipeng Sui
, Robert N. Helsley
, Se Hyung Park
, Shuxia Wang
, Richard N. Greenberg
, Changcheng Zhou

Producción científica: Comment/debate

Resumen

It has come to our attention that there was a mistake in Fig. 6 in the published version of our manuscript. The mistake occurred during the publication process and has resulted in the labelling being inverted for the treatments with emtricitabine and efavirenz in the graph in Fig. 6A. Please see the corrected figure above. We apologize for any inconvenience caused.

Idioma original	English
Páginas (desde-hasta)	1003-1004
Número de páginas	2
Publicación	Journal of Hepatology
Volumen	74
N.º	4
DOI	https://doi.org/10.1016/j.jhep.2021.01.003
Estado	Published - abr 2021

Nota bibliográfica

Publisher Copyright:
© 2019 European Association for the Study of the Liver

ASJC Scopus subject areas

Hepatology

Acceder al documento

10.1016/j.jhep.2021.01.003

Otros archivos y enlaces

Huella

Profundice en los temas de investigación de 'Erratum: Non-nucleoside reverse transcriptase inhibitor efavirenz activates PXR to induce hypercholesterolemia and hepatic steatosis (Journal of Hepatology (2019) 70(5) (930–940), (S0168827819300297), (10.1016/j.jhep.2018.12.038))'. En conjunto forman una huella única.

Citar esto

Gwag, T., Meng, Z., Sui, Y., Helsley, R. N., Park, S. H., Wang, S., Greenberg, R. N., & Zhou, C. (2021). Erratum: Non-nucleoside reverse transcriptase inhibitor efavirenz activates PXR to induce hypercholesterolemia and hepatic steatosis (Journal of Hepatology (2019) 70(5) (930–940), (S0168827819300297), (10.1016/j.jhep.2018.12.038)). Journal of Hepatology, 74(4), 1003-1004. https://doi.org/10.1016/j.jhep.2021.01.003

@article{378d6c7fe39048e0846ed21388edaa1e,

title = "Erratum: Non-nucleoside reverse transcriptase inhibitor efavirenz activates PXR to induce hypercholesterolemia and hepatic steatosis (Journal of Hepatology (2019) 70(5) (930{\textendash}940), (S0168827819300297), (10.1016/j.jhep.2018.12.038))",

abstract = "It has come to our attention that there was a mistake in Fig. 6 in the published version of our manuscript. The mistake occurred during the publication process and has resulted in the labelling being inverted for the treatments with emtricitabine and efavirenz in the graph in Fig. 6A. Please see the corrected figure above. We apologize for any inconvenience caused.",

author = "Taesik Gwag and Zhaojie Meng and Yipeng Sui and Helsley, \{Robert N.\} and Park, \{Se Hyung\} and Shuxia Wang and Greenberg, \{Richard N.\} and Changcheng Zhou",

note = "Publisher Copyright: {\textcopyright} 2019 European Association for the Study of the Liver",

year = "2021",

month = apr,

doi = "10.1016/j.jhep.2021.01.003",

language = "English",

volume = "74",

pages = "1003--1004",

number = "4",

}

Gwag, T, Meng, Z, Sui, Y, Helsley, RN, Park, SH, Wang, S , Greenberg, RN & Zhou, C 2021, 'Erratum: Non-nucleoside reverse transcriptase inhibitor efavirenz activates PXR to induce hypercholesterolemia and hepatic steatosis (Journal of Hepatology (2019) 70(5) (930–940), (S0168827819300297), (10.1016/j.jhep.2018.12.038))', Journal of Hepatology, vol. 74, n.º 4, pp. 1003-1004. https://doi.org/10.1016/j.jhep.2021.01.003

Erratum: Non-nucleoside reverse transcriptase inhibitor efavirenz activates PXR to induce hypercholesterolemia and hepatic steatosis (Journal of Hepatology (2019) 70(5) (930–940), (S0168827819300297), (10.1016/j.jhep.2018.12.038)). / Gwag, Taesik; Meng, Zhaojie; Sui, Yipeng et al.
En: Journal of Hepatology, Vol. 74, N.º 4, 04.2021, p. 1003-1004.

Producción científica: Comment/debate

TY - JOUR

T1 - Erratum

T2 - Non-nucleoside reverse transcriptase inhibitor efavirenz activates PXR to induce hypercholesterolemia and hepatic steatosis (Journal of Hepatology (2019) 70(5) (930–940), (S0168827819300297), (10.1016/j.jhep.2018.12.038))

AU - Gwag, Taesik

AU - Meng, Zhaojie

AU - Sui, Yipeng

AU - Helsley, Robert N.

AU - Park, Se Hyung

AU - Wang, Shuxia

AU - Greenberg, Richard N.

AU - Zhou, Changcheng

PY - 2021/4

Y1 - 2021/4

N2 - It has come to our attention that there was a mistake in Fig. 6 in the published version of our manuscript. The mistake occurred during the publication process and has resulted in the labelling being inverted for the treatments with emtricitabine and efavirenz in the graph in Fig. 6A. Please see the corrected figure above. We apologize for any inconvenience caused.

AB - It has come to our attention that there was a mistake in Fig. 6 in the published version of our manuscript. The mistake occurred during the publication process and has resulted in the labelling being inverted for the treatments with emtricitabine and efavirenz in the graph in Fig. 6A. Please see the corrected figure above. We apologize for any inconvenience caused.

UR - https://www.scopus.com/pages/publications/85100320763

UR - https://www.scopus.com/pages/publications/85100320763#tab=citedBy

U2 - 10.1016/j.jhep.2021.01.003

DO - 10.1016/j.jhep.2021.01.003

M3 - Comment/debate

C2 - 33526292

AN - SCOPUS:85100320763

SN - 0168-8278

VL - 74

SP - 1003

EP - 1004

JO - Journal of Hepatology

JF - Journal of Hepatology

IS - 4

ER -

Gwag T, Meng Z, Sui Y, Helsley RN, Park SH, Wang S et al. Erratum: Non-nucleoside reverse transcriptase inhibitor efavirenz activates PXR to induce hypercholesterolemia and hepatic steatosis (Journal of Hepatology (2019) 70(5) (930–940), (S0168827819300297), (10.1016/j.jhep.2018.12.038)). Journal of Hepatology. 2021 abr;74(4):1003-1004. doi: 10.1016/j.jhep.2021.01.003